Effect of the CRTH2 Antagonist OC459 on the Response to Rhinovirus Challenge in Asthma

Trial Profile

Effect of the CRTH2 Antagonist OC459 on the Response to Rhinovirus Challenge in Asthma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs OC 459 (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms ORCA
  • Most Recent Events

    • 13 Jul 2017 Planned number of patients changed from 34 to 44.
    • 10 Jun 2017 Biomarkers information updated
    • 24 Dec 2016 Planned number of patients changed to 34.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top